The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has now enrolled more than 50,000 women and secured 111 study sites in the United States and abroad. One of the fastest growing National Cancer Institute (NCI)–sponsored trials, TMIST participation has doubled since the start of the COVID-19 pandemic.